Unlocking the Potential of CBLC: A promising Drug Target and Biomarker for Ubiquitin-Protein Ligase E3

Target Name: CBLC

NCBI ID: G23624

CBLC

Unlocking the Potential of CBLC: A promising Drug Target and Biomarker for Ubiquitin-Protein Ligase E3

Introduction

Ubiquitin-protein ligase (E3) is a crucial enzyme in the ubiquitin system, which plays a pivotal role in regulating protein degradation and cell signaling. The CBLC (CBL-C) gene encodes an E3 ubiquitin-protein ligase that has been identified as a potential drug target and biomarker. In this article, we will explore the biology of CBLC and its potential as a drug target, as well as its potential as a biomarker for various diseases.

The CBLC Gene and its Function

CBLC, or CBL-C, is a member of the E3 ubiquitin-protein ligase family. This family of enzymes plays a central role in the regulation of protein degradation by the ubiquitin system. CBLC is responsible for the conversion of the ubiquitin precursor, ubiquitin , into its active form, which is then involved in protein degradation.

The CBLC gene encodes a protein that contains a single polypeptide chain composed of 21 amino acids. This protein has a molecular weight of 20 kDa and a calculated pI of 4.95. CBLC is expressed in most tissues and cells, and its levels vary depending on the specific cell type and the level of protein degradation in the cell.

CBLC's Unique Features

CBLC has several unique features that make it an attractive drug target and biomarker. One of its main advantages is its high catalytic activity. CBLC has a kcat (catalytic activity) value of 29 sg/substrate, which is much higher than that of other E3 ubiquitin-protein ligases. This high catalytic activity makes CBLC an ideal candidate for drug development.

Another unique feature of CBLC is its ability to target specific proteins for degradation. CBLC can target protein species with different molecular weight and stability, which allows it to play a broad role in the regulation of protein degradation. This makes CBLC an attractive target for drug development , especially for diseases characterized by the accumulation of misfolded or misregulated proteins.

CBLC's Potential as a Drug Target

CBLC's high catalytic activity and ability to target specific proteins make it an attractive drug target. Various studies have suggested that CBLC may be a potential drug target for a variety of diseases, including neurodegenerative diseases, cancer, and autoimmune diseases.

One of the reasons why CBLC has been identified as a potential drug target is its involvement in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the accumulation of misfolded proteins and the loss of normal cellular structures. CBLC has been shown to play a role in the regulation of the degradation of normal proteins, including those involved in neurotransmitter synthesis and release, which is thought to contribute to the development of neurodegenerative diseases.

In addition to its potential role in neurodegenerative diseases, CBLC has also been suggested as a potential drug target for cancer. Cancer is characterized by the accumulation of misfolded or mutated proteins, which can lead to the development of a variety of aggressive and refractory diseases. CBLC has been shown to play a role in the regulation of protein degradation in cancer cells, which may contribute to the development and progression of these conditions.

CBLC's Potential as a Biomarker

CBLC may also be used as a biomarker for various diseases. One of the main advantages of CBLC is its ability to serve as a protein biomarker due to its high stability and expression levels. This makes CBLC a potential biomarker for a variety of diseases, including neurodegenerative diseases, cancer, and autoimmune diseases.

CBLC has been shown to be involved in the regulation of protein degradation in a variety of diseases, including neurodegenerative diseases. For example, studies have shown that CBLC is involved in

Protein Name: Cbl Proto-oncogene C

Functions: Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR. Isoform 1, but not isoform 2, inhibits EGF stimulated MAPK1 activation. Promotes ubiquitination of SRC phosphorylated at 'Tyr-419'. In collaboration with CD2AP may act as regulatory checkpoint for Ret signaling by modulating the rate of RET degradation after ligand activation; CD2AP converts it from an inhibitor to a promoter of RET degradation; the function limits the potency of GDNF on neuronal survival

The "CBLC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBLC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets